You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. SBIR PHASE I- WEARABLE BIOSENSOR THAT QUANTIFIES BLOOD ALCOHOL CONCENTRATION IN REAL TIME

    SBC: SUGPIAT DEFENSE, LLC            Topic: NIAAA

    Testing Bio Sole biosensor as a wearable technology to quantify BAC in real time

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. A Self-Replicating RNA Vaccine Against HIV-1 Delivered Using A Nanoparticle Adjuvant

    SBC: PAI Life Sciences, Inc.            Topic: NIAID

    An effective vaccine against HIV offers the best chance to stop the global epidemic but remains elusive to dateResearch has primarily focused on subunit monomerice ggpor gpor trimeric antigensthe former approachoften adjuvanted with alumhas failed in clinical trialsNative like trimers mimic the Env spike but are still poorly immunogenic and require elaborate adjuvant screening efforts to potentiat ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Prophylactic Onchocerciasis Vaccine

    SBC: PAI Life Sciences, Inc.            Topic: NIAID

    Humanriver blindnessis caused by a filarial parasite and is a serious neglected tropical disease contributing to blindnessskin diseaseand chronic disability in the developing worldEstimates from the Global Burden of Disease Studyindicate thatmillion cases of onchocerciasisleading tomillion cases of vision impairmentoccur worldwide every yearThe goal of this project is to develop a safe and effecti ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Rational Development of a Combination Nanoparticle Adjuvant for Influenza

    SBC: HDT Bio Corp.            Topic: NIAID

    SignificanceHighly pathogenic avian H Ninfluenzawhich has killedpeople sinceis poised to cause a pandemic in a worldwide population that has no pre existing immunityCurrent Hvaccines are insufficiently immunogenic without the addition of adjuvantsbut responses to these adjuvanted vaccines are not durable and may not be protective against newly emergent viral strainsProposed solutionWe have develop ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Discovery of new small molecule TLR4 agonists for the treatment of allergic rhinitis

    SBC: DiaCarta            Topic: NIAID

    This pilot study is aimed at judging the efficacy of the lead compound with a clinically relevant allergenThe relevant allergen chosen for this study is the house dust mite Dermatophagoides pteronyssinus allergenDer pLoToxTM Natural Der pfrom Indoor Biotechnologies with a low endotoxin contentEUgWe are selecting this allergen because our team has extensive prior experience with this allergen in mo ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Acoustic Scaffold Bioreactor

    SBC: RESODYN CORPORATION            Topic: NHLBI

    This Small Business Innovation Research Phase II project will develop a commercially viable device that uses micro scale acoustic streaminglow frequency sound energyto deliver mixing to the interior of three dimensionalDscaffolds used for stem cell cultivation applicationsThe enabling advantage of low frequency sound energy is the ability to generate micro scale mixing in and around scaffolds that ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects

    SBC: Syntrix Biosystems, Inc.            Topic: NIDA

    Fromthe utilization of the Schedule II opioids codeineOxyContin and fentanyl declined significantlydown aboutfor all three drugsIn sharp contrastthe use of tramadola Schedule IV controlled substanceincreasedSchedule IV substances have low potential for abuse and harm relative to Schedule II substancesand the fortuitous trend to tramadol has reduced the use of the relatively unsafe Schedule II opio ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Immuno Oncology Product for Multiple Myeloma: g-NK Cellular Therapy to Optimize Monoclonal Antibody Efficacy in Treating Multiple

    SBC: Indapta Therapeutic            Topic: 102

    Project Summary Abstract Multiple myeloma is the second most common hematologic malignancy in the USwith aboutnew cases in the US each yearMost patients with MM relapse and eventually become unresponsive to treatmentAlthough multiple new therapies for MM have come on the markettheir promise is limited by concerns about toxicity and low efficacyand MM remains incurableThereforethere is an urgentdem ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Translational development of specialized NK cells for cancer immunotherapy

    SBC: Indapta Therapeutic            Topic: 102

    Project Summary Abstract The annual incidence of head and neck cancers worldwide is more thancases with arounddeaths each yearand it is estimated that inthere will benew cases of non Hodgkin lymphoma with an estimateddeaths this yearIn this proposalwe describe a strategy to use a novel subset of natural killer cellsg NK cellsallogeneically for cancer therapyWe hypothesize that expansion and adopti ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Production and Validation of Sj-p80 as a Veterinary Schistosomiasis Vaccine

    SBC: PAI Life Sciences, Inc.            Topic: NIAID

    Project Summary More thanbillion people are at risk worldwide for developing schistosomiasis caused by one of five species of SchistosomaTwo species that cause the most human diseaseSchistosoma japonicum and Schistosoma mansoniinfect the intestine and liver by similar processesbut differ in their geographically distributionNeither are thought to be containedand both have increased their global foo ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government